This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 May;13(7):746.

EGFR R521K predicts cetuximab response in KRAS wild-type patients

Affiliations

Affiliation

¹ Faculty of Pharmacy & Pharmaceutical Sciences, 3142F Katz Group Centre for Pharmacy & Health Research, University of Alberta, Edmonton, AB, T6G 2E1, Canada. smarsh@pharmacy.ualberta.ca

PMID: 22754965

Comment

EGFR R521K predicts cetuximab response in KRAS wild-type patients

Sharon Marsh. Pharmacogenomics. 2012 May.

. 2012 May;13(7):746.

Author

Affiliation

¹ Faculty of Pharmacy & Pharmaceutical Sciences, 3142F Katz Group Centre for Pharmacy & Health Research, University of Alberta, Edmonton, AB, T6G 2E1, Canada. smarsh@pharmacy.ualberta.ca

PMID: 22754965

No abstract available

PubMed Disclaimer

Comment on

Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy.
Hsieh YY, Tzeng CH, Chen MH, Chen PM, Wang WS. Hsieh YY, et al. Cancer Sci. 2012 Apr;103(4):791-6. doi: 10.1111/j.1349-7006.2012.02225.x. Epub 2012 Feb 22. Cancer Sci. 2012. PMID: 22321154 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal